Aktienanalyse zu Stryker Corp (SYK)SYKStryker Corp

Stryker Corporation is a medical technology company. It offers products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Its segments include MedSurg and Neurotechnology and Orthopaedics. Its MedSurg products include surgical equipment, patient and caregiver safety technologies, and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), and patient handling, emergency medical equipment, intensive care disposable products and clinical communication and artificial intelligence-assisted virtual care platform technology (Medical). Neurotechnology includes neurosurgical, neurovascular and craniomaxillofacial implant products. Its Orthopaedics primarily include implants used in total joint replacements, such as hip, knee and shoulder, and others. It offers solutions for venous thromboembolism clot removal without the use of thrombolytic drugs. It is also focused on treating calcified arterial disease. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Stryker Corp is currently priced at $294.66, which is below several analyst price targets, including $316 from BTIG and $375 from Barclays. However, the recent RSI of 78.996 indicates that the stock is overbought, suggesting caution. Additionally, hedge funds are selling, with a 119.77% increase in selling activity over the last quarter, indicating potential negative sentiment. Therefore, while there are positive catalysts such as the FDA clearance of Sonopet 3, the overall market sentiment and insider selling suggest holding rather than buying at this time.

27 analysts cover SYK: 17 rate it Buy, 8 Hold and 2 Sell. The average price target is 430.32.